Search the database for deliberate release of GM medicinal products
| EU record number |
Title |
Company / Sponsor |
Treated organism |
Genetic modification |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukaemia |
Institut de Recherches Internationales Servier |
Humans |
chimeric antigen receptor and suicide-ligand (RQR8) |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
A phase 1 randomized, placebo-controlled, double-blind, dose escalation trial to evaluate the safety and immunogenicity of tgAAC09, a gag-PR-DRT AAV HIV vaccine |
International AIDS Vaccine Initiative (IAVI) |
Humans |
genes for the gag, protease and part of the reverse transcriptase proteins of HIV-1 |
| Only notified under the "contained use" procedure. Dossier submitted on
. |
A phase III, multi-center, open-label, randomized study to compare the overall survival and safety of bi-weekly intratumoral administration of INGN 201 versus weekly methotrewate in 240 patients with refractory squamous cell carcinoma of the head and neck |
Introgen Therapeutics, Inc. |
Humans |
Wild-type p53 |
